In‐Hospital Worsening Heart Failure and Associations With Mortality, Readmission, and Healthcare Utilization-Reference-Cited by-同舟云学术

In‐Hospital Worsening Heart Failure and Associations With Mortality, Readmission, and Healthcare Utilization

Published:2014-08-15 Issue:4 Volume:3 Page:
ISSN:2047-9980
Container-title:Journal of the American Heart Association
language:en
Short-container-title:JAHA

Author:

DeVore Adam D.¹²,Hammill Bradley G.¹,Sharma Puza P.³,Qualls Laura G.¹,Mentz Robert J.¹²,Waltman Johnson Katherine³,Fonarow Gregg C.⁴,Curtis Lesley H.¹²,Hernandez Adrian F.¹²

Affiliation:

1. Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC

2. Department of Medicine, Duke University School of Medicine, Durham, NC

3. Novartis Pharmaceuticals Corporation, East Hanover, NJ

4. Ahmanson‐UCLA Cardiomyopathy Center, University of California, Los Angeles, CA

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Reference18 articles.

1. Heart Disease and Stroke Statistics—2013 Update

2. National and Regional Trends in Heart Failure Hospitalization and Mortality Rates for Medicare Beneficiaries, 1998-2008

3. Heart Failure Incidence and Survival (from the Atherosclerosis Risk in Communities Study)

4. Effects of Tezosentan on Symptoms and Clinical Outcomes in Patients With Acute Heart Failure

5. Rolofylline, an Adenosine A1−Receptor Antagonist, in Acute Heart Failure

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acute Heart Failure;Cardiology Clinics;2024-05

2. Cost–Utility Analysis of Vericiguat in Heart Failure with Reduced Ejection Fraction After Worsening Heart Failure Events in China;American Journal of Cardiovascular Drugs;2024-04-15

3. Organ perfusion pressure at admission and clinical outcomes in patients hospitalized for acute heart failure;European Heart Journal: Acute Cardiovascular Care;2023-10-26

4. Piora Hospitalar da Insuficiência Cardíaca: Podemos Prevê-la na Admissão?;Arquivos Brasileiros de Cardiologia;2023-08

5. Cost‐utility analysis of add‐on dapagliflozin in heart failure with preserved or mildly reduced ejection fraction;ESC Heart Failure;2023-06-08